Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00622700




Registration number
NCT00622700
Ethics application status
Date submitted
14/02/2008
Date registered
25/02/2008
Date last updated
13/03/2017

Titles & IDs
Public title
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
Scientific title
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Secondary ID [1] 0 0
HMR1726D-3005
Secondary ID [2] 0 0
EFC6260
Universal Trial Number (UTN)
Trial acronym
TOPIC
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Teriflunomide
Treatment: Drugs - Placebo

Placebo comparator: Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg - Core treatment period: Placebo matched to teriflunomide tablet once daily orally.

Extension treatment period: Re-randomized in 1:1 ratio to either teriflunomide 7 mg or 14 mg once daily orally.

Experimental: Teriflunomide 7 mg/7 mg - Core treatment period: Teriflunomide 7 mg tablet once daily orally.

Extension treatment period: Teriflunomide 7 mg tablet once daily orally.

Experimental: Teriflunomide 14 mg/14 mg - Core treatment period: Teriflunomide 14 mg tablet once daily orally.

Extension treatment period: Teriflunomide 14 mg tablet once daily orally.


Treatment: Drugs: Teriflunomide
Film-coated tablet Oral administration

Treatment: Drugs: Placebo
Film-coated tablet Oral administration
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Core Treatment Period: Time to Conversion to Clinically De?nite Multiple Sclerosis (CDMS)
Timepoint [1] 0 0
Up to a maximum of 108 weeks depending on time of enrollment
Secondary outcome [1] 0 0
Core Treatment Period: Time to Conversion to Definite Multiple Sclerosis (DMS)
Timepoint [1] 0 0
Up to a maximum of 108 weeks depending on time of enrollment
Secondary outcome [2] 0 0
Core Treatment Period: Annualized Relapse Rate (ARR)
Timepoint [2] 0 0
Up to a maximum of 108 weeks depending on time of enrollment
Secondary outcome [3] 0 0
Core Treatment Period: Brain Magnetic Resonance Imaging (MRI) Assessment: Change From Baseline in Total Lesion Volume at Week 108
Timepoint [3] 0 0
Baseline, Week 108
Secondary outcome [4] 0 0
Core Treatment Period: Brain MRI Assessment: Number of Gadolinium Enhancing (Gd-enhancing) T1-lesions Per MRI Scan (Poisson Regression Estimates)
Timepoint [4] 0 0
Up to a maximum of 108 weeks depending on time of enrollment
Secondary outcome [5] 0 0
Core Treatment Period: Brain MRI Assessment: Volume of Gadolinium Enhancing (Gd-enhancing) T1-lesions Per MRI Scan
Timepoint [5] 0 0
Up to a maximum of 108 weeks depending on time of enrollment
Secondary outcome [6] 0 0
Core Treatment Period: Brain MRI Assessment: Change From Baseline in Volume of Hypointense Post-Gadolinium T1 Lesion Component
Timepoint [6] 0 0
Baseline, Week 108
Secondary outcome [7] 0 0
Core Treatment Period: Brain MRI Assessment: Change From Baseline in Volume of T2 Lesion Component
Timepoint [7] 0 0
Baseline, Week 108
Secondary outcome [8] 0 0
Core Treatment Period: Brain MRI Assessment: Percent Change From Baseline in Atrophy
Timepoint [8] 0 0
Baseline, Week 108
Secondary outcome [9] 0 0
Core Treatment Period: Time to 12-Week Sustained Disability Progression
Timepoint [9] 0 0
Up to a maximum of 108 weeks depending on time of enrollment
Secondary outcome [10] 0 0
Core Treatment Period: Change From Baseline in EDSS at Week 108
Timepoint [10] 0 0
Baseline, Week 108
Secondary outcome [11] 0 0
Core Treatment Period: Change From Baseline in Fatigue Impact Scale (FIS) Total Score at Week 108
Timepoint [11] 0 0
Baseline, Week 108
Secondary outcome [12] 0 0
Core Treatment Period: Overview of Adverse Events (AEs)
Timepoint [12] 0 0
From first study drug intake up to 112 days after last intake in the placebo-controlled period or up to first intake in the extension treatment period, whichever occurred first
Secondary outcome [13] 0 0
Extension Treatment Period: Time to Conversion to Clinically De?nite Multiple Sclerosis (CDMS)
Timepoint [13] 0 0
From randomization in the core period up to 390 Weeks (Extension treatment period [maximum exposure: 283 Weeks])
Secondary outcome [14] 0 0
Extension Treatment Period: Overview of Adverse Events (AEs)
Timepoint [14] 0 0
From re-randomization up to 283 Weeks

Eligibility
Key inclusion criteria
* First acute or subacute, well-defined neurological event consistent with demyelination (that is, optic neuritis confirmed by an ophthalmologist, spinal cord syndrome, brainstem/cerebellar syndromes)
* Onset of MS symptoms occurring within 90 days of randomization
* A screening MRI scan with 2 or more T2 lesions at least 3 millimeter (mm) in diameter that are characteristic of MS
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease
* Significantly impaired bone marrow function
* Pregnancy or nursing
* Alcohol or drug abuse
* Use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment
* Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2016
Sample size
Target
Accrual to date
Final
618
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Investigational Site Number 1405 - Geelong
Recruitment hospital [2] 0 0
Investigational Site Number 1404 - Heidelberg
Recruitment hospital [3] 0 0
Investigational Site Number 1407 - Hobart
Recruitment hospital [4] 0 0
Investigational Site Number 1401 - Parkville
Recruitment postcode(s) [1] 0 0
3220 - Geelong
Recruitment postcode(s) [2] 0 0
3081 - Heidelberg
Recruitment postcode(s) [3] 0 0
7001 - Hobart
Recruitment postcode(s) [4] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Indiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Louisiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
New Mexico
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Tennessee
Country [14] 0 0
United States of America
State/province [14] 0 0
Vermont
Country [15] 0 0
United States of America
State/province [15] 0 0
Washington
Country [16] 0 0
Austria
State/province [16] 0 0
Innsbruck
Country [17] 0 0
Austria
State/province [17] 0 0
Linz
Country [18] 0 0
Austria
State/province [18] 0 0
Wien
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Pleven
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Sofia
Country [21] 0 0
Canada
State/province [21] 0 0
Greenfield Park
Country [22] 0 0
Canada
State/province [22] 0 0
London
Country [23] 0 0
Canada
State/province [23] 0 0
Montreal
Country [24] 0 0
Canada
State/province [24] 0 0
Ottawa
Country [25] 0 0
Canada
State/province [25] 0 0
Quebec
Country [26] 0 0
Canada
State/province [26] 0 0
Sherbrooke
Country [27] 0 0
Canada
State/province [27] 0 0
Toronto
Country [28] 0 0
Chile
State/province [28] 0 0
Santiago
Country [29] 0 0
Chile
State/province [29] 0 0
Viña Del Mar
Country [30] 0 0
Czech Republic
State/province [30] 0 0
Brno
Country [31] 0 0
Czech Republic
State/province [31] 0 0
Hradec Kralove
Country [32] 0 0
Czech Republic
State/province [32] 0 0
Olomouc
Country [33] 0 0
Czech Republic
State/province [33] 0 0
Ostrava - Poruba
Country [34] 0 0
Denmark
State/province [34] 0 0
Aarhus C
Country [35] 0 0
Denmark
State/province [35] 0 0
Esbjerg
Country [36] 0 0
Estonia
State/province [36] 0 0
Tallinn
Country [37] 0 0
Estonia
State/province [37] 0 0
Tartu
Country [38] 0 0
Finland
State/province [38] 0 0
Helsinki
Country [39] 0 0
Finland
State/province [39] 0 0
Kuopio
Country [40] 0 0
Finland
State/province [40] 0 0
Turku
Country [41] 0 0
France
State/province [41] 0 0
Besancon
Country [42] 0 0
France
State/province [42] 0 0
Clermont Ferrand Cedex 1
Country [43] 0 0
France
State/province [43] 0 0
Lille Cedex
Country [44] 0 0
France
State/province [44] 0 0
Montpellier Cedex 05
Country [45] 0 0
France
State/province [45] 0 0
Nancy Cedex
Country [46] 0 0
France
State/province [46] 0 0
Nantes Cedex 01
Country [47] 0 0
France
State/province [47] 0 0
Nice Cedex
Country [48] 0 0
France
State/province [48] 0 0
Nimes
Country [49] 0 0
France
State/province [49] 0 0
Strasbourg Cedex
Country [50] 0 0
Germany
State/province [50] 0 0
Bayreuth
Country [51] 0 0
Germany
State/province [51] 0 0
Berlin
Country [52] 0 0
Germany
State/province [52] 0 0
Erbach
Country [53] 0 0
Germany
State/province [53] 0 0
Essen
Country [54] 0 0
Germany
State/province [54] 0 0
Hannover
Country [55] 0 0
Germany
State/province [55] 0 0
Ludwigshafen
Country [56] 0 0
Germany
State/province [56] 0 0
Minden
Country [57] 0 0
Germany
State/province [57] 0 0
Münster
Country [58] 0 0
Germany
State/province [58] 0 0
Wiesbaden
Country [59] 0 0
Hungary
State/province [59] 0 0
Budapest
Country [60] 0 0
Hungary
State/province [60] 0 0
Esztergom
Country [61] 0 0
Hungary
State/province [61] 0 0
Veszprém
Country [62] 0 0
Lithuania
State/province [62] 0 0
Klaipeda
Country [63] 0 0
Lithuania
State/province [63] 0 0
Siauliai
Country [64] 0 0
Lithuania
State/province [64] 0 0
Vilnius
Country [65] 0 0
Mexico
State/province [65] 0 0
Chihuahua
Country [66] 0 0
Mexico
State/province [66] 0 0
Guadalajara
Country [67] 0 0
Poland
State/province [67] 0 0
Gdansk
Country [68] 0 0
Poland
State/province [68] 0 0
Lodz
Country [69] 0 0
Poland
State/province [69] 0 0
Warszawa 44
Country [70] 0 0
Poland
State/province [70] 0 0
Warszawa
Country [71] 0 0
Romania
State/province [71] 0 0
Bucuresti
Country [72] 0 0
Romania
State/province [72] 0 0
Cluj-Napoca
Country [73] 0 0
Romania
State/province [73] 0 0
Timisoara
Country [74] 0 0
Russian Federation
State/province [74] 0 0
Kazan
Country [75] 0 0
Russian Federation
State/province [75] 0 0
Nizhny Novgorod
Country [76] 0 0
Russian Federation
State/province [76] 0 0
Novosibirsk
Country [77] 0 0
Russian Federation
State/province [77] 0 0
Rostov-On-Don
Country [78] 0 0
Russian Federation
State/province [78] 0 0
Smolensk
Country [79] 0 0
Russian Federation
State/province [79] 0 0
St-Petersburg
Country [80] 0 0
Turkey
State/province [80] 0 0
Edirne
Country [81] 0 0
Turkey
State/province [81] 0 0
Istanbul
Country [82] 0 0
Turkey
State/province [82] 0 0
Izmir
Country [83] 0 0
Turkey
State/province [83] 0 0
Izmit
Country [84] 0 0
Turkey
State/province [84] 0 0
Trabzon
Country [85] 0 0
Ukraine
State/province [85] 0 0
Chernihiv
Country [86] 0 0
Ukraine
State/province [86] 0 0
Dnipropetrovsk
Country [87] 0 0
Ukraine
State/province [87] 0 0
Donets'K
Country [88] 0 0
Ukraine
State/province [88] 0 0
Kharkiv
Country [89] 0 0
Ukraine
State/province [89] 0 0
Kiev
Country [90] 0 0
Ukraine
State/province [90] 0 0
Lutsk
Country [91] 0 0
Ukraine
State/province [91] 0 0
Lviv
Country [92] 0 0
Ukraine
State/province [92] 0 0
Poltava
Country [93] 0 0
Ukraine
State/province [93] 0 0
Vinnytsya
Country [94] 0 0
Ukraine
State/province [94] 0 0
Zaporizhzhya
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Liverpool
Country [96] 0 0
United Kingdom
State/province [96] 0 0
London
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Newcastle Upon Tyne
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Nottingham
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Plymouth
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Salford
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Sanofi
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective was to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day \[mg/day\] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical episode consistent with multiple sclerosis (MS) to clinically definite multiple sclerosis (CDMS).

The secondary objectives were:

* To demonstrate the effect of teriflunomide, in comparison to placebo, on:

* Reducing conversion to definite multiple sclerosis (DMS)
* Reducing annualized relapse rate (ARR)
* Reducing disease activity/progression as measured by Magnetic Resonance Imaging (MRI)
* Reducing accumulation of disability for at least 12 weeks as measured by the Expanded Disability Status Scale (EDSS)
* Proportion of disability-free participants as assessed by the EDSS
* Reducing participant-reported fatigue
* To evaluate the safety and tolerability of teriflunomide
* To evaluate the pharmacokinetics (PK) of teriflunomide
* Optional pharmacogenomic testing aimed at assessing the association between the main enzyme systems of teriflunomide metabolism and hepatic safety, and other potential associations between gene variations and clinical outcomes
Trial website
https://clinicaltrials.gov/study/NCT00622700
Trial related presentations / publications
Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; TOPIC Study Group. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Oct;13(10):977-86. doi: 10.1016/S1474-4422(14)70191-7. Epub 2014 Sep 2.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Sciences & Operations
Address 0 0
Sanofi
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00622700